Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

540
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
540
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

55
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
55
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

89
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
89
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

102
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
102
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.7K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.7K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

122
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
122

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ITM2B-associated retinal dystrophy mutation modifies BRI23 peptide interactions in the human retina.

Scientific reports·2026
Same author

Vitamin D status and <i>Helicobacter pylori</i> infection: clinical associations and lipid pathway differences in an exploratory metabolomics sub-study.

Frontiers in nutrition·2026
Same author

Genotype before phenotype? Reversing the diagnostic odyssey in genomic medicine.

European journal of medical genetics·2026
Same author

Association of post-transcriptional regulatory gene single nucleotide polymorphisms with Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same author

Long-read Sequencing in Inherited Retinal Dystrophies: A Systematic Review.

Ophthalmology science·2026
Same author

A novel HPS3 pathogenic nonsense variant associated with Hermansky-Pudlak syndrome type 3 and a platelet dysfunction.

Molecular biology reports·2025

Related Experiment Video

Updated: Nov 18, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.9K

Pharmacogenetics in developing countries and low resource environments.

Said El Shamieh1, Nathalie K Zgheib2

  • 1Department of Medical Laboratory Technology, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon.

Human Genetics
|February 10, 2021
PubMed
Summary

Pharmacogenetics (PGx) research and clinical use lag in developing nations. Bridging this gap requires global collaboration, capacity building, and advanced technologies like next-generation sequencing.

More Related Videos

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

17.0K
Design and Use of a Low Cost, Automated Morbidostat for Adaptive Evolution of Bacteria Under Antibiotic Drug Selection
10:50

Design and Use of a Low Cost, Automated Morbidostat for Adaptive Evolution of Bacteria Under Antibiotic Drug Selection

Published on: September 27, 2016

10.0K

Related Experiment Videos

Last Updated: Nov 18, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.9K
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

17.0K
Design and Use of a Low Cost, Automated Morbidostat for Adaptive Evolution of Bacteria Under Antibiotic Drug Selection
10:50

Design and Use of a Low Cost, Automated Morbidostat for Adaptive Evolution of Bacteria Under Antibiotic Drug Selection

Published on: September 27, 2016

10.0K

Area of Science:

  • Pharmacogenetics
  • Genomics
  • Global Health

Background:

  • Pharmacogenetics (PGx) has advanced significantly in developed economies.
  • However, PGx remains nascent in developing countries and low-resource settings.

Purpose of the Study:

  • To identify the research and clinical gaps in PGx in developing countries.
  • To propose strategies for advancing PGx in these regions.

Main Methods:

  • Comparative analysis of PGx research output, researcher numbers, and citations.
  • Assessment of clinical implementation challenges.

Main Results:

  • Developing countries show significantly lower PGx research activity and output.
  • Clinical PGx implementation progresses slower in developing nations compared to research.

Conclusions:

  • Fostering regional and multinational collaborations is crucial for funding and capacity building.
  • Implementing next-generation sequencing and specialized training programs are recommended to advance PGx research and clinical applications.